AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9400
-0.1100 (-5.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0500
Open2.0300
Bid0.0000 x 1100
Ask0.0000 x 900
Day's Range1.9000 - 2.2000
52 Week Range1.5600 - 9.2000
Volume1,093,633
Avg. Volume751,711
Market Cap36.618M
Beta (3Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-1.1370
Earnings DateSep 27, 2018 - Sep 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...

  • Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today
    InvestorPlace

    Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

    Some recent biopharma news concerning Akari Therapeutics has AKTX stock flying high on Wednesday.Source: Shutterstock The biopharma news has to do with Akari Therapeutics (NASDAQ:AKTX) getting Fast Track designation from the U.S. Food & Drug Administration (FDA) for one of its treatments. This allows the company to speed up testing of the drug. The designation is typically given to medicine with potential to treat illnesses that don't already have wide coverage.The Fast Track designation from the FDA is for Akari Therapeutics' nomacopan. This is the company's drug for treating HSCT-TMA. HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children that suffer from it. There currently isn't an approved treatment for this illness.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe positive biopharma news for AKTX stock comes after the successful treating of two patients in the U.S. with nomacopan. With these results and the FDA's approval, the company is now planning to launch a clinical trial of the treatment in the fourth quarter of 2019. * 15 Growth Stocks to Buy for the Long Haul "We see HSCT-TMA as a gateway into a range of other poorly treated orphan TMAs in both pediatric and adult patients, and are optimistic about the potential for nomacopan to offer an improved standard of care for these orphan conditions with high mortality rates," Clive Richardson, interim CEO of Akari Therapeutics, said in a statement.AKTX stock was up 32% as of Wednesday morning and is up 7% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch

    Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

    Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S. Food and Drug Administration. Trading volume swelled to 1.7 million shares, compared with the full-day average of about 96,000 shares. A Fast Track designation helps facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening conditions that address unmet medical needs. ""Fast Track designation provides our HSCT-TMA clinical program a pathway for an expedited approval for nomacopan, and we plan to commence a pivotal trial in the fourth quarter of 2019," said Chief Executive Clive Richardson. The stock has tumbled 42% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 2.9% and the S&P 500 has tacked on 3.2%.

  • GlobeNewswire

    Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

    Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designation follows a successful pre-investigational new drug (IND) FDA meeting earlier this year regarding Akari’s proposed pivotal clinical trial program for HSCT-TMA. The FDA is working with Akari in its optimization of pediatric dosing for HSCT-TMA by Akari’s participation in the FDA Model-Informed Drug Development (MIDD) Program with supportive PK data provided by pediatric patients already treated with nomacopan as part of a named patient program.

  • GlobeNewswire

    Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).

  • GlobeNewswire

    Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced an oral presentation will be given at the 28th EADV Congress. The oral presentation will describe the safety and efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild to moderate bullous pemphigoid.

  • Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility

    Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share...

  • Alexion's Ultomiris Receives EU Approval for PNH in Adults
    Zacks

    Alexion's Ultomiris Receives EU Approval for PNH in Adults

    Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

  • GlobeNewswire

    Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with certain institutional investors, accredited investors and an existing shareholder, RPC Pharma Ltd., an affiliated entity of Dr. Ray Prudo, Akari’s Chairman, to receive gross proceeds of $4.5 million. In connection with the offering, the Company will issue approximately 2,368,421 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.90 per ADS in a registered direct offering.

  • Alexion Receives FDA Approval for Label Expansion of Soliris
    Zacks

    Alexion Receives FDA Approval for Label Expansion of Soliris

    Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
    Zacks

    Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

    Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

  • Benzinga

    Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation

    Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The secondary objective of efficacy was assessed using a standard composite scoring system. Atopic keratoconjunctivitis is a serious corneal and eye surface disease which ultimately leads to visual impairment.

  • GlobeNewswire

    Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)

    Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. All patients were on maximal dosage of cyclosporin, the standard of care, for at least three months prior to treatment. Improvement in the composite clinical score was seen in signs and symptoms reflecting the potential for both reduced corneal damage and improved patient comfort.

  • GlobeNewswire

    Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trialsFurther clinical data from BP and AKC trials.

  • ACCESSWIRE

    FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet

    - Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks into the headlines. Recent examples include Mustang Bio (MBIO) and Akari Therapeutics (AKTX) with their respective human study results.

  • GlobeNewswire

    Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases

    In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants.

  • Benzinga

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • GlobeNewswire

    Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease.

  • ACCESSWIRE

    Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs

    CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Today we are highlighting: Akari Therapeutics, Plc (AKTX), Twitter Inc. (TWTR), Bank of America Corporation (BAC), Leafbuyer Technologies, Inc. (LBUY). Akari Therapeutics, Plc (AKTX) (Market Cap: $65.409M) traded higher on Tuesday 4/23/2019 after making a big announcement.

  • Benzinga

    Microcap Biotech Akari Rallies On Coversin Trial Results

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...

  • GlobeNewswire

    Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.

  • GlobeNewswire

    Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will provide an update on its eye diseases program during the 2019 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) being held April 28-May 2, 2019 in Vancouver, B.C. A poster will be presented at ARVO showing Coversin’s effect in a preclinical model of autoimmune uveitis, a back of the eye orphan disease with significant unmet need.

  • ACCESSWIRE

    These Tech Stocks Could Test March Highs

    CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've seen tech companies design and invent in the areas of data analytics, artificial intelligence, augmented reality, and a plethora of others. ParcelPal Technology Inc (PTNYF) (PKG), Conformis Inc (CFMS), Digital Turbine Inc (APPS), and Akari Therapeutics Plc (AKTX) represent 4 tech stocks on the rise on Monday.

  • What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St.

    What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?

    Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...